ASTRACT
INTRODUCTION
Squamous-cell carcinoma of the head and neck (SCCHN), the sixth most frequent tumor in the world, is characterized by the infiltration of different subsets of tumor-infiltrating lymphocytes (TILs or CD3 ϩ cells). 1 TILs are present in a greater amount in the earlier stages of SCCHN disease, with the relative proportion of CD3 ϩ CD4 ϩ or T-helper cells being higher than, or at least equal to, CD3 ϩ CD8 ϩ suppressor/cytotoxic T-cells. 2 Of interest, a subset of CD3 ϩ CD4 ϩ cells in SCCHN express CD25 (the interleukin-2 receptor [IL-2R] alpha chain). CD25 is expressed on CD3 ϩ CD4 ϩ cells following the activation by recognition of nonself antigens or tumor-associated antigens. SCCHN tumor-associated antigens include CEA, NY-ESO-1, MAGE-1, and MAGE-3. Activated CD3 ϩ CD4 ϩ CD25 ϩ cells may inhibit tumor growth by lysing tumor cells or by secreting cytokines interferon-gamma ([IFN-␥], tumor necrosis factor [TNF] ␣, and so forth). 3, 4 Activated CD3 ϩ CD4 ϩ CD25 ϩ cells may also play a major cooperative role for CD3 ϩ CD4 ϩ CD8 ϩ cells in in vivo tumor eradication and the promotion of recruitment of other antitumor effector cells, for example, macrophages and eosinophils. [5] [6] [7] In SCCHN cell lines, expression of CD25 ϩ has been reported to be either absent, low, or high. [8] [9] [10] [11] In only one study, respectively, by Wiedeman et al., human tissue SCCHN samples were studied. 10 In this study, a low to absent expression of CD25 was observed on SCCHN tumor cells; however, only four resection specimens were analyzed. Also, the relationship between CD25 expression on SCCHN and patient outcome is currently unknown.
This study reports on the expression of CD25 on lymphocytes and on SCCHN tumor cells assessed by means of immunohistochemistry, on instantly snap-frozen resection or biopsy specimens of primary human SCCHN, obained in a consecutive series of 35 patients. Histologic results obtained were related to overall, diseasefree survival.
PATIENTS AND METHODS

Patients
This study was approved by the Ethics committee of the University Hospital Ghent (Ghent, Belgium). Thirty-five (35) successive patients with a clinical or iconographic suggestive SCCHN were included in the study following written, informed consent over a period of 1 year, starting in June 2001. All patients underwent a systematic staging after a direct laryngoscopy and tissue biopsy diagnosis with planar chest radiographs, serum chemistry, and liver function analyses, and a contrast-enhanced computed tomography (CT) scan of the head and neck. The American Joint Committee on Cancer (AJCC) version 6 tumor node metastases (TNM) criteria were used for stage delineation. Baseline staging incorporated all physical findings, diagnostic imaging, and available pathology results. In all patients, treatment was performed with curative intent and consisted of definitive resection, with or without adjuvant radiotherapy, or primary radiotherapy, with or without combined lymph node dissection of the neck, and with or without chemotherapy. After the completion of treatment, patients underwent routine surveillance every 1-3 months. In all patients, a tumor specimen or biopsy was obtained prior to treatment instigation, immediately snap frozen by using liquid nitrogen, and imbedded in a conservation medium and conserved by Ϫ80°C.
Methods
Assessment of the level of inflammation
To assess the degree of inflammation, hematoxylin and eosin (H&E)-stained sections from neutral buffered formalin-fixed tissue were scored in a blinded fashion by using a five-point scale: 0, no inflammation; 1, very weak level of inflammation; 2, weak level of inflammation; 3, moderate level of inflammation; and 4, high level of inflammation.
Evaluation of CD25 on tumor specimens
Five-millimeter (5 mm) sections were freed of paraffin, and endogenous peroxidase activity was blocked with H 2 O 2 . A primary antibody-targeting human CD25 (1:200 dilution; neoMarkers) was incubated for 1 hour at room temperature, followed by a secondary antibody incubation (biotinylated goat antimouse, 1:40 dilution) for 30 minutes at room temperature. Then, avidin biotin amplification (ABC kit; Dakocytomation, Glostrup, Denmark) was added for 30 minutes. Incubation with an AEC (3-amino-9-ethylcarbazole) chromogen kit (Sigma, St. Louis, MO) at room temperature for 5-10 minutes produced a red reaction pigment. CD25-positive tumor cells and lymphocytes were counted separately at a magnification of 400ϫ by using a test grid with a 0.22-mm 2 area. Intensities of staining were classified from 0 (absent staining) to 4 (high staining). A score of 1, 2, or 3 corresponds, respectively, with very low, low, and intermediate intensity of staining. For each malignancy, a value designated as HSCORE was obtained after the application of the following algorithm for both tumor cells and lymphocytes: HSCORE ϭ ⌺(I ϩ 1)xn, where I and n represent the number of cells that stained at each intensity, respectively. Double staining for CD3 and CD25 was performed to demonstrate that T-lymphocytes were CD25 positive. Sections were first incubated with monoclonal antibodies to CD25, then the reaction was revealed by incubating the sections with a streptavidin-fluorescein conjugate (fluorescein isothiocyanate). After the first reaction, a second reaction with primary antibodies to CD3 was induced, and fluorescence was obtained with a streptavidin-Texas red fluorescent conjugate. Control sections were incubated with a mixture of irrelevant monoclonal reagents with a similar isotype. Images were acquired by means of the Noran (Naarden, The Netherlands) confocal microscope, and three-dimensional stacks were acquired at a resolution of 0.1 m in the x, y, and z axes.
Statistical analysis
Statistical analysis was performed by using the commercially available software package SPSS (Chicago, IL), version 12.0. The KolmogorovSmirnov test was used to check the normality of data distribution. Quantitative variables were compared by using a paired Student's t test and analysis of variance or the Mann-Whitney and Kruskall-wallis tests if their distribution was not normal. Qualitative variables were compared by using the chi-square test. Correlation analysis was performed by using the two-tailed Pearson test in the case of normally distributed data or the Spearman-rank test in the case of not normal distributed data. Disease-free survival times were calculated from the date of definitive radiotherapy completion or the date of definitive surgery. Persistent or recurrent disease at a presenting primary site was scored as local disease failure. Disease-free survival took into account all disease events, including local, regional, and distant failures. Patients with persistent disease at the end of treatment were considered to have experienced failure at time zero. Patients with no signs of relapse were censored at the time of last follow-up or death. Overall survival was defined as the time from initial diagnosis until death or until last follow-up (right censored data). Overall survival took all deaths into account. For univariate and regression analysis, we dichotomized values according to the median values of the study cohort or either defined the best separating cut-off value. We dichotomized the following clinical covariates: T-stage (T0-T2 vs. T3-T4), N stage (N0-N1 vs. N2-N3), AJCC overall stage (stages I-III vs. IV) and age (Ͻ60 years vs. Ն60 years). Local recurrence-free, as well as overall, survival times were estimated by the Kaplan-Meier method and log rank testing (two-tailed) to examine the predictive value of dichotomized values and other clinical risk factors for local disease control. Multivariate analysis was performed by using Cox regression analysis, including, in sequential order of statistical significance, those variables that were found to be significant in univariate analysis, followed by the interactive terms.
RESULTS
Patient Characteristics
Mean age of the patient population under study was 60.5 years (range, 43-82), and patient characteristics are presented in Table 1 . Regional lymph node involvement was diagnosed in 22 patients (63%). There were 8 women and 27 men. Six (6) patients presented with stage II disease, 7 suffered from stage III disease, and 22 patients suffered from stage IV disease.
In 9 patients, treatment consisted of resection of the primary tumor with unilateral lymph node dissection (n ϭ 5), with bilateral lymph node dissection (n ϭ 1), or without lymph node dissection (n ϭ 3). In 19 patients, treatment consisted of resection of the primary tumor with unilateral lymph node dissection (n ϭ 15), with bilateral lymph node dissection (n ϭ 1), or without lymph node dissection (n ϭ 3), followed by adjuvant radiotherapy (cumulative dose, 60-70 Gy). Three (3) patients were treated by means of primary radiotherapy (cumulative dose, 70-75 Gy), in 2 of these patients after a unilateral and bilateral lymph node dissection. Finally, 4 patients were treated by means of radiochemotherapy (cumulative dose of 70 Gy combined with cisplatin at a dose of 100 mg/m 2 on days 1, 22, and 43). Two (2) out of these 4 patients first underwent unilateral lymph node dissection and 1 patient bilateral lymph node dissection. Data on the presence of human papilloma or Epstein-Barr virus were not available.
Histologic Characterization
CD25, on lymphoid cells
Twenty-five (25) The number of CD25-positive lymphocytes was significantly higher than the number of CD25-positive neoplastic cells, respectively (p ϭ 0.006). CD25 lymphocyte HScore was significantly higher than the CD25 tumor-cell HScore (p ϭ 0.001).
Finally, the number of CD25-positive neoplastic cells and corresponding HScores did not correlate with the respective number of CD25-positive lymphocytes or Hscores. 
Disease-Free Survival
Median disease-free survival in the patients included in our study was 13.8 months (range, 2.2-42.1 months). On univariate analysis, only lymph node status dichotomized according to N0-N1 versus N2-N3 disease and the number of CD25-positive lymphocytes dichotomized by using a cut-off of Ն45 cells field of view, were predictive of recurrence-free survival (p ϭ 0.039 and 0.04) (see Table 2 and Fig. 2 ). The median diseasefree survival for patients with N0-N1 disease was 15.1 months, versus 12.6 months for patients with N2-N3 disease. The median disease-free survival for patients with low numbers of SCCHN CD25 ϩ infiltrating lymphocytes was 11.1 months (n ϭ 20), versus 32.8 months for patients with high numbers of SCCHN CD25 ϩ infiltrating lymphocytes (n ϭ 15). When both factors were included in the multivariate model, only the number of CD25-positive lymphocytes showed an association with diseasefree survival (p ϭ 0.036 for the number of CD25 positive lymphocytes versus p ϭ 0.249 for lymph node status) (see Table 3 ).
Overall survival
At the time of data analysis, 15 patients had died and 93.3% of deaths seemed to be directly related to the original primary cancer (locoregional failure or metastatic disease). One (1) patient committed suicide. The median follow-up for the whole population was 17.6 months (range, 2.2-55.1 months). On univariate analysis, only LN status dichotomized according to N0-N1 versus N2-N3 disease and the level of SCCHN infiltrating CD25 ϩ lymphocytes were predictive of overall survival (p ϭ 0.007 and 0.02; see Fig. 3 ). Median overall survival for patients with N0-N1 disease was 27.9 months, versus 12.6 months for patients with N2-N3 disease. Median overall survival for patients with low numbers of SCCHN CD25 ϩ infiltrating lymphocytes was 13.7 months, versus 39.4 months for patients with high numbers of SCCHN CD25 ϩ infiltrating lymphocytes (see Table 2 ). When both factors were included in the multivariate model, both N-status and the number of CD25 positive lymphocytes showed an independent association with overall survival (p ϭ 0.007 for the number of CD25-positive lymphocytes and p ϭ 0.003 for lymph node status) (see Table 3 ).
DISCUSSION
In this study, we show that high levels of tumorinfiltrating CD25 ϩ T-lymphocytes are signifi- cantly associated with better survival and especially with locoregional control in SCCHN patients. Available data on the potential prognostic value of T-cell infiltrations in SCCHN are limited. In a series of 16 patients by Snyderman et al., 2 of 8 patients with a CD4 ϩ /CD8 ϩ ratio of less than 1 developed cervical metastases, whereas 6 of 8 patients with a CD4 ϩ /CD8 ϩ ratio greater than 1 developed cervical metastases. 12 Based on their findings, the researchers suggested that a CD4 ϩ /CD8 ϩ ratio greater than 1 may be a useful prognostic indicator of the development of cervical metastases. More recently, Badoual et al. reported on the prognostic value of tumor-infiltrating CD4 ϩ CD25 ϩ T-cells and Tcell subpopulations in a series of 84 newly diagnosed, untreated patients with histologically proven primary head and neck cancer. 13 Although not statistically significant, a trend toward longer survival (p ϭ 0.059) and better locoregional control (p ϭ 0.054) was observed in the group of patients with a high level of tumor-infiltrating CD25 ϩ T-cells at diagnosis. In the series presented, the number of tumor-infiltrating CD4 ϩ CD25 ϩ T-cells at the time of diagnosis proved of significant prognostic value for both disease-free and overall survival in multivariate analysis. In the series by Badoual et al., the median of tumor infiltration for CD4 ϩ CD25 ϩ Tcells was used to dichotomize patients in highand low-level groups of CD4 ϩ CD25 ϩ T-cells, whereas in our series, the best separating value (i.e., the value higher than the median value) was used. Given the trend observed in their series, it is highly likely that by optimizing their cut-off value, similar results to ours would have been obtained. In the series by Badoual et al., CD25 ϩ cells were further subdivided in two subsets for data analysis, respectively, in true helper effector T-cells (CD4 ϩ CD25 ϩ CD69 ϩ ) and in regulatory T-cells (CD4 ϩ CD25 ϩ Foxp3 ϩ or Treg cells). [14] [15] [16] [17] 8 Our series is the first that reports on the expression of CD25 ϩ on SCCHN tumors in a larger series of patients, documenting SCCHN CD25 expression cells in 18 of 35 patients under study, albeit with mild to moderate intensity. Overexpression of CD25 on SCCHN tumor cells has been associated with tumor progression. 22 Reported underlying molecular mechanisms responsible for the association between CD25 expression and tumor progression include Janus kinase 3 (Jak-3)-mediated increase in levels of cyclin-A, cyclin D, and cyclin-dependent kinases 2 and 4, resulting in an increase in cell proliferation, as well as the upregulation of antiapoptotic BcX-(L) and Bcl-2 proteins, resulting in an increased resistance to chemotherapeutics. 22 In the series presented, the number of CD25-positive tumor cells or related HScore proved not different between different histologic tumor grades, nor was there a relationship between either of these factors and disease-free or overall survival (regardless of the cut-off value used for dichotomization). Of interest, in the study by Cortesina et al., doses of 8-500 U/mL of IL-2 were able to inhibit the growth of 11 of 16 SCCHN lines tested. 8 Also, in an immunosuppressed SCCHN xenografted nude mouse model, both locally and systemically administered rIL-2 significantly inhibited the growth of SCCHN. The absence of a significant inflammatory infiltrate in or around the xeno-grafts in this model, related to the immunosuppression, argued strongly for a direct effect of IL-2 on tumor cells, rather than for an effector host macrophage-mediated effect. 23 In this light, assessment of the relationship between the level of CD25 ϩ expression on SCCHN cells to outcome to IL-2 therapy may be of interest.
CONCLUSIONS
In conclusion, the presence of a high number of SCCHN-infiltrating CD25 ϩ lymphocytes is associated with a good prognosis in SCCHN patients. Contrarywise, CD25 ϩ expression on SC-CHN tumor was not related to patient outcome.
